Send to

Choose Destination
Hamostaseologie. 2016 Nov 8;36(Suppl. 2):S5-S12.

Regulatory T cells and their potential for tolerance induction in haemophilia A patients.

Author information

Anja Schmidt, Biochemist, PhD, Molekulare Hämostaseologie & Immundefizienz, Universitätsklinikum Frankfurt, Klinik für Kinder- und Jugendmedizin, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany, Tel. +49/(0)69/630 18-57 12, Fax -39 91, Email:


FVIII inhibitors still are the major concern in treatment of haemophilia A patients by FVIII replacement therapy. Immune tolerance induction to reverse inhibitor formation fails in about 30% of treated patients. These patients face increased morbidity and mortality producing a need for new therapy strategies in the treatment of FVIII inhibitor-positive patients. Regulatory T cells are important modulators of the immune response and are also involved in the immune response to FVIII in haemophilia A patients. Additionally, regulatory T cells have been shown to play a role in tolerance induction induced by multiple experimental treatment regimes. This review summarises the current knowledge on the role of regulatory T cells in the immune response to FVIII and tolerance induction strategies. Additionally, possible ways to engineer regulatory T cells as therapeutic agent in haemophilia A and current challenges of regulatory T cell therapies are discussed.


Haemophilia A; regulatory T cells; tolerance

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center